Android app on Google Play

Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside

January 15, 2013 7:12 AM EST Send to a Friend
Get Alerts REGN Hot Sheet
Price: $362.94 +3.56%

Rating Summary:
    16 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 13 | New: 52
Trade REGN Now!
Join SI Premium – FREE
Jefferies downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold with a price target of $179.00.

The firm sees limited Eylea upside after conducting another wAMD survey. The firm said the current stock prices adequately reflects anticipated growth. Benefit from potential cmpding driven decline in Avastin use only modestly benefits Eylea, according to the firm.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $179.40 yesterday.




You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Jefferies & Co

Add Your Comment